BioSpace News Archive

According to the new market research report “Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro and In-Vivo),

The Insight Partners published latest research study on “Synthetic Biology Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Products (Enzymes, Chassis Organisms, Oligonucleotides, and Xeno-Nucleic Acids), Technology (Measurement & Modeling, Cloning & Sequencing

The Insight Partners published latest research study on “Cardiovascular Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Device [Electrocardiography (ECG)

SpectronRx will open its first European facility on SCK CEN’s premises

BioSyent Inc. released its financial results for the three months ended March 31, 2023.

Ipsen announced that the re-examination of palovarotene as a potential treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva, by the Committee for Medicinal Products for Human Use of the European Medicines Agency confirms the negative opinion given in January 2023.

Biological Dynamics announced the publication of a case report, “Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy,” in Frontiers in Oncology, highlighting the successful detection of early-stage pancreatic ductal adenocarcinoma lesions using its exosome liquid biopsy assay, ExoVitaTM Pancreas.

eFFECTOR Therapeutics, Inc. announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 11,450,382 shares of its common stock, at a purchase price of $0.655 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced the commencement of CAR-T NXC-201 Engineering Batches at its U.S. Manufacturing Site. These U.S. engineering batches will support the planned U.S. expansion of the Company’s ongoing Phase 1b/2a NEXICART-1 study of its novel BCMA-targeted chimeric antigen receptor T cell therapy NXC-201.

Nexcella, Inc., announced the commencement of CAR-T NXC-201 Engineering Batches at its U.S. Manufacturing Site. These U.S. engineering batches will support the planned U.S. expansion of the Company’s ongoing Phase 1b/2a NEXICART-1 study of its novel BCMA-targeted chimeric antigen receptor T cell therapy NXC-201.